Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors

Fineline Cube Sep 18, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial

Fineline Cube Sep 18, 2025

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...

Company Deals

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China

Fineline Cube Sep 18, 2025

Eisai (TYO: 4523) China, operating through its subsidiary Eisai (Liaoning) Pharmaceutical Co., Ltd., announced a...

Company Deals

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth

Fineline Cube Sep 18, 2025

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...

Company Drug

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B

Fineline Cube Sep 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...

Company Deals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies

Fineline Cube Sep 18, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...

Company Drug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Fineline Cube Sep 18, 2025

A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...

Company Deals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

Fineline Cube Sep 18, 2025

Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...

Drug Policy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Fineline Cube Sep 18, 2025

The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...

Company Deals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Fineline Cube Sep 18, 2025

Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...

Company Deals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Fineline Cube Sep 17, 2025

Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...

Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

Fineline Cube Sep 17, 2025

Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...

Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Fineline Cube Sep 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...

Company Drug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Fineline Cube Sep 17, 2025

Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...

Company Deals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Fineline Cube Sep 17, 2025

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...

Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

Fineline Cube Sep 17, 2025

The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...

Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Fineline Cube Sep 17, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...

Company Drug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Fineline Cube Sep 17, 2025

Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...

Company Deals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Fineline Cube Sep 17, 2025

InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...

Company Deals Drug

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Fineline Cube Sep 17, 2025

Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson & Johnson (J&J,...

Posts pagination

1 … 154 155 156 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.